{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-012000","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.684286+00:00","generated_at":"2026-05-20T18:08:47.169208+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lipocine's LPCN 1148 for cirrhosis highlighted in Hepatology journal","bullets":["LPCN 1148 for men with cirrhosis featured in 'Hepatology Highlights' in June 2025 edition of Hepatology.","Article contributed by Dr. Kevin Harris of Mayo Clinic; Phase 2 results published in same issue.","FDA granted fast track designation for LPCN 1148 as treatment for sarcopenia in decompensated cirrhosis.","CEO Mahesh Patel highlighted growing recognition of LPCN 1148's potential to improve cirrhosis outcomes.","Company is exploring partnering opportunities for LPCN 1148."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-012000","json":"https://secwatch.observer/filing/0001641172-25-012000.json","markdown":"https://secwatch.observer/filing/0001641172-25-012000.md","text":"https://secwatch.observer/filing/0001641172-25-012000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225012000/0001641172-25-012000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225012000/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T18:08:47.169208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}